Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: $ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acrivon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acrivon Therapeutics's position in the market.
News
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is developing precision oncology medicines using its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The company's president and CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on February 13, 2024, at 2:40 p.m. ET. The live webcast can be accessed on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. announced the approval of an equity award under its 2023 Inducement Plan to one employee in the form of stock options. The employee received options to purchase 99,300 shares of Acrivon common stock, with vesting conditions and installments. The grant was approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and was granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) announced that its president and CEO, Peter Blume-Jensen, M.D., Ph.D., will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference. Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The webcast will be available on the company's website with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) appoints Jean-Marie Cuillerot, M.D., as chief medical officer and announces other key personnel updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) has announced that the FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. The designation reflects FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Acrivon has partnered with Akoya Biosciences to co-develop, validate, and commercialize ACR-368 OncoSignature assay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) announced the participation of its president and CEO in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference. The company is a clinical stage biopharmaceutical firm developing precision oncology medicines utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
Rhea-AI Summary
Acrivon Therapeutics, Inc. (ACRV) granted an equity award to one employee, consisting of 57,900 stock options, under its 2023 Inducement Plan. The options will vest over a three-year period, subject to continued employment, as part of a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.02%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) reported Q3 2023 financial results and business highlights, emphasizing commitment to precision oncology medicines and the Acrivon Predictive Precision Proteomics (AP3) platform. CEO Peter Blume-Jensen highlighted recent presentations and initial clinical readouts for ACR-368, with more data to be presented in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.19%
Tags
-
Rhea-AI Summary
Acrivon Therapeutics grants equity awards to two employees under its 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
Rhea-AI Summary
Acrivon Therapeutics announces selection of two abstracts for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
Acrivon Therapeutics, Inc.
Nasdaq:ACRV
ACRV Rankings
ACRV Stock Data
264.29M
3.98M
17.57%
69.76%
2.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
WATERTOWN
About ACRV
acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities